High-Density Lipoprotein Vascular Protective Effects, Dysfunction, and Potential as Therapeutic Target

被引：228

作者：

Luescher, Thomas F. ^{[1
,3
]}

Landmesser, Ulf ^{[1
,3
]}

von Eckardstein, Arnold ^{[2
]}

Fogelman, Alan M. ^{[4
]}

机构：

[1] Univ Zurich Hosp, Dept Cardiol, Univ Heart Ctr, CH-8091 Zurich, Switzerland

[2] Univ Zurich Hosp, Dept Clin Chem, CH-8091 Zurich, Switzerland

[3] Univ Zurich, Inst Physiol, Div Cardiovasc Res, Zurich, Switzerland

[4] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA

来源：

CIRCULATION RESEARCH | 2014年 / 114卷 / 01期

基金：

新加坡国家研究基金会; 美国国家卫生研究院;

关键词：

apolipoprotein A-I; cholesterol; HDL; nitric oxide; REVERSE CHOLESTEROL TRANSPORT; APOLIPOPROTEIN-A-I; CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; NITRIC-OXIDE SYNTHASE; B TYPE-I; BINDING CASSETTE TRANSPORTER; TYPE-2; DIABETES-MELLITUS; ENDOTHELIAL NO SYNTHASE; ESTER TRANSFER PROTEIN;

D O I：

10.1161/CIRCRESAHA.114.300935

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-density lipoprotein (HDL) is a complex mixture of lipoproteins that is associated with many minor proteins and lipids that influence the function of HDL. Although HDL is a promising marker and potential therapeutic target based on its epidemiological data and the effects of healthy HDL in vitro in endothelial cells and macrophages, as well as based on infusion studies of reconstituted HDL in patients with hypercholesterolemia, it remains still uncertain whether or not HDL cholesterol-raising drugs will improve outcomes. Recent studies suggest that HDL becomes modified in patients with coronary artery disease or acute coronary syndrome because of oxidative processes that result in alterations in its proteome composition (proteome remodelling) leading to HDL dysfunction.

引用

页码：171 / 182

页数：12

共 113 条

[1] Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment [J].

Ansell, BJ ;

Navab, M ;

Hama, S ;

Kamranpour, N ;

Fonarow, G ;

Hough, G ;

Rahmani, S ;

Mottahedeh, R ;

Dave, R ;

Reddy, ST ;

Fogelman, AM .

CIRCULATION, 2003, 108 (22) :2751-2756

[2]

Attie AD, 2001, J LIPID RES, V42, P1717

[3] HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].

Barter, Philip ;

Gotto, Antonio M. ;

LaRosa, John C. ;

Maroni, Jaman ;

Szarek, Michael ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Bittner, Vera ;

Fruchart, Jean-Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310

[4] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[5] Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: A randomized placebo-controlled clinical trial [J].

Bertrand, Olivier F. ;

Poirier, Paul ;

Rodes-Cabau, Josep ;

Rinfret, Stephane ;

Title, Lawrence M. ;

Dzavik, Vladimir ;

Natarajan, Madhu ;

Angel, Juan ;

Batalla, Nuria ;

Almeras, Natalie ;

Costerousse, Olivier ;

De Larochelliere, Robert ;

Roy, Louis ;

Despres, Jean-Pierre .

ATHEROSCLEROSIS, 2010, 211 (02) :565-573

[6] Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease [J].

Besler, Christian ;

Luescher, Thomas F. ;

Landmesser, Ulf .

EMBO MOLECULAR MEDICINE, 2012, 4 (04) :251-268

[7] Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease [J].

Besler, Christian ;

Heinrich, Kathrin ;

Rohrer, Lucia ;

Doerries, Carola ;

Riwanto, Meliana ;

Shih, Diana M. ;

Chroni, Angeliki ;

Yonekawa, Keiko ;

Stein, Sokrates ;

Schaefer, Nicola ;

Mueller, Maja ;

Akhmedov, Alexander ;

Daniil, Georgios ;

Manes, Costantina ;

Templin, Christian ;

Wyss, Christophe ;

Maier, Willibald ;

Tanner, Felix C. ;

Matter, Christian M. ;

Corti, Roberto ;

Furlong, Clement ;

Lusis, Aldons J. ;

von Eckardstein, Arnold ;

Fogelman, Alan M. ;

Luescher, Thomas F. ;

Landmesser, Ulf .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (07) :2693-2708

[8] Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients [J].

Bloedon, LeAnne T. ;

Dunbar, Richard ;

Duffy, Danielle ;

Pinell-Salles, Paula ;

Norris, Robert ;

DeGroot, Bruce J. ;

Movva, Rajesh ;

Navab, Mohamad ;

Fogelman, Alan M. ;

Rader, Daniel J. .

JOURNAL OF LIPID RESEARCH, 2008, 49 (06) :1344-1352

[9] Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].

Boden, William E. ;

Probstfield, Jeffrey L. ;

Anderson, Todd ;

Chaitman, Bernard R. ;

Desvignes-Nickens, Patrice ;

Koprowicz, Kent ;

McBride, Ruth ;

Teo, Koon ;

Weintraub, William .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267

[10] Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial [J].

Bots, Michiel L. ;

Visseren, Frank L. ;

Evans, Gregory W. ;

Riley, Ward A. ;

Revkin, James H. ;

Tegeler, Charles H. ;

Shear, Charles L. ;

Duggan, William T. ;

Vicari, Ralph M. ;

Grobbee, Diederick E. ;

Kastelein, John J. .

LANCET, 2007, 370 (9582) :153-160

← 1 2 3 4 5 6 7 8 9 10 →